Doses Of Cryoprecipitate Research Articles

Dose Requirement for Replacement Therapy in Hemophilia A

In order to determine the correlation between different doses of F. VIII and their clinical effect, 70 children with severe hemophilia A were studied after treatment with single doses of cryoprecipitate. The relationship between plasma F. VIII levels or doses calculated in u/kg of body weight and clinical results followed an exponential curve. Plasma F. VIII levels of 0.35 and 0.53 u/ml corresponded to 95 and 99% satisfactory treatment, respectively. Similar clinical results were obtained with 20 and 31 u/kg. When the in vivo recovery of F. VIII after lyophilized cryoprecipitate was 0.015 u/ml for each u/kg injected, plasma F. VIII levels of 0.30 and 0.47 u/ml respectively were achieved. Since home treatment is largely based on single infusions of F. VIII, it is suggested that moderate and severe hemorrhages be treated with a dose which will provide a plasma F. VIII level of 0.5 u/ml.

Acquired circulating anticoagulant to factor VIII. Response to high doses of cryoprecipitate and immunosuppressive therapy

Acquired circulating anticoagulant to factor VIII. Response to high doses of cryoprecipitate and immunosuppressive therapy

The Treatment of Patients Having Spontaneously Occurring Antibodies to Antihaemophilic Factor (Factor VIII)

SummaryThe appearance of antibodies to factor VIII in the blood of previously normal people is a very rare occurrence but when it does happen the haemorrhagic condition which results can be very serious and difficult to treat.From experience of three cases described here it is recommended that treatment be witheld unless there is serious haemorrhage in which case steroids, large doses of cryoprecipitate or other human AHG should be given. In the case of life endangering haemorrhages it is justified to use the much more potent animal AHG preparations along with an immuno-suppressive drug.